Moraxella catarrhalis is a bacterium that lives in the human respiratory tract and causes ear infections in young children, flare-ups of chronic lung disease in adults, and occasionally pneumonia or sinusitis. Once dismissed as a harmless bystander, it gained recognition over the past few decades as a genuine pathogen, partly because nearly all strains now produce enzymes that break down common antibiotics like amoxicillin. That combination of widespread colonization, real clinical impact, and growing resistance makes it worth understanding in some detail.
A Bacterium That Changed Its Reputation
For most of the twentieth century, Moraxella catarrhalis (previously called Branhamella catarrhalis or Neisseria catarrhalis) was treated as a normal, harmless resident of the nose and throat. Clinicians who cultured it from sputum or middle-ear fluid often assumed it was a contaminant rather than the culprit. That view shifted as better microbiological tools and clinical studies accumulated, and the organism is now firmly classified as a significant human pathogen.1PubMed Central. Moraxella catarrhalis: from emerging to established pathogen Under the microscope it appears as gram-negative diplococci, meaning pairs of round cells that do not retain the crystal violet stain used in basic lab identification. It is oxidase-positive, does not ferment sugars, and grows well on standard blood agar at body temperature.
Who Carries It and How Common Is Colonization
M. catarrhalis colonizes the upper respiratory tract of a large fraction of healthy people, but colonization rates vary dramatically by age. In healthy adults, roughly five percent carry the organism in their nose or throat at any given time, while about half of young children carry it.2PubMed Central. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum In older adults, particularly those over sixty, the carriage rate climbs back up to roughly a quarter of people.3PubMed Central. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum
Colonization starts early in life. A Dutch birth-cohort study found that about twelve percent of infants carried the bacterium by six weeks of age, and that proportion rose to about thirty percent by six months, holding steady through the first fourteen months.4Clinical Microbiology and Infection. Determinants of Moraxella catarrhalis colonization in healthy Dutch children during the first 14 months of life A study of kindergarten-age children in Nepal found nasal carriage in close to sixty percent of healthy kids.5PubMed Central. Prevalence of Moraxella Catarrhalis as a Nasal Flora among Healthy Kindergarten Children in Bhaktapur, Nepal The high childhood colonization rate matters because it overlaps with the age window when ear infections are most common.
Ear Infections in Children
Acute otitis media, the medical term for a middle-ear infection, is one of the most frequent reasons parents bring young children to a doctor. M. catarrhalis is consistently identified as one of the three leading bacterial causes, alongside Streptococcus pneumoniae and Haemophilus influenzae. How large a share it accounts for depends on the detection method. A large Israeli study of nearly 13,000 ear infection episodes over many years found M. catarrhalis by standard culture in about five percent of culture-positive cases.6PubMed. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics However, a Finnish study using the more sensitive PCR method detected M. catarrhalis in close to half of middle-ear fluid samples from young children with ear infections, suggesting culture substantially underestimates its presence.7PubMed Central. Moraxella catarrhalis Might Be More Common than Expected in Acute Otitis Media in Young Finnish Children
M. catarrhalis ear infections tend to be somewhat milder than those caused by the other two major pathogens. The Israeli study found that M. catarrhalis was more likely to appear as part of a mixed infection rather than as the sole pathogen, and it was associated with lower rates of eardrum perforation compared to the other bacteria. None of the M. catarrhalis episodes in that study led to mastoiditis, a serious complication involving the bone behind the ear.8PubMed. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics That said, “milder” is relative; ear infections still cause significant pain, fever, and sometimes hearing difficulties, and recurrent episodes can affect language development in young children.
COPD Exacerbations in Adults
For adults, the most important clinical role of M. catarrhalis is triggering flare-ups (exacerbations) of chronic obstructive pulmonary disease, or COPD. People with COPD already have damaged airways, and when they acquire a new strain of M. catarrhalis, it can push them from their baseline level of breathing difficulty into a more acute episode with increased cough, sputum, and shortness of breath.
A landmark study published in the New England Journal of Medicine tracked COPD patients over time and found that acquiring a new strain of H. influenzae, M. catarrhalis, or S. pneumoniae roughly doubled the risk of an exacerbation compared to clinic visits where no new bacterial strain was found.9PubMed. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease A separate study focused specifically on M. catarrhalis found that about half of new acquisitions led to an exacerbation.10American Journal of Respiratory and Critical Care Medicine. Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease: Burden of Disease and Immune Response Even when the bacterium did not trigger a full exacerbation, its arrival in the airways provoked measurable inflammation: levels of key inflammatory markers in sputum rose significantly after M. catarrhalis colonization, whether or not the patient experienced symptoms bad enough to qualify as an exacerbation.11PubMed Central. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease
Pneumonia and Other Infections
Beyond ear infections and COPD flare-ups, M. catarrhalis causes community-acquired pneumonia, sinusitis, and bronchitis. Pneumonia caused by this bacterium tends to show up in older adults who already have underlying lung conditions like asthma or bronchiectasis, and it has a seasonal lean toward winter months. A retrospective study comparing M. catarrhalis pneumonia to pneumococcal pneumonia found that M. catarrhalis patients were older on average and more likely to have pre-existing pulmonary disease.12PubMed Central. Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults: a retrospective single-centre study
Invasive disease, where the bacterium gets into the bloodstream, is rare but not unheard of. A review of 58 cases of M. catarrhalis bacteremia found that underlying conditions played a major role in both how the infection presented and how the patient fared. The outlook was particularly poor for patients with endocarditis or those who had weakened immune defenses due to immunoglobulin deficiency or low white blood cell counts.13PubMed. Spectrum and significance of bacteremia due to Moraxella catarrhalis Case reports have documented unusual scenarios like endocarditis paired with spinal bone infection in an immunosuppressed patient.14BMJ Case Reports. Infectious endocarditis and vertebral osteomyelitis caused by Moraxella catarrhalis Bacteremia-associated pneumonia is also uncommon enough that individual cases still get published in the literature.15PubMed Central. Community-Acquired Moraxella catarrhalis Bacteremic Pneumonia: Two Case Reports and Review of the Literature For the average healthy person, these invasive complications are extremely unlikely, but they are a real concern in immunocompromised populations.
How the Bacterium Sticks Around and Evades the Immune System
M. catarrhalis has a toolkit of surface proteins that help it attach to human cells and resist being killed. The most studied of these are the ubiquitous surface proteins UspA1 and UspA2. UspA1 acts as an adhesin, helping the bacterium cling to epithelial cells lining the airway. It binds to proteins on the surface of those cells, including fibronectin and a receptor family called CEACAMs.16PubMed. A novel cell-binding mechanism of Moraxella catarrhalis ubiquitous surface protein UspA: specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by UspA1 Without UspA1, the bacterium’s ability to adhere to and invade epithelial cells drops steeply.17Microbes and Infection. Outer membrane protein UspA1 and lipooligosaccharide are involved in invasion of human epithelial cells by Moraxella catarrhalis UspA1 also plays a role in biofilm formation, where clusters of bacteria embed themselves in a protective matrix on mucosal surfaces.18PubMed Central. Biofilm formation by Moraxella catarrhalis in vitro: roles of the UspA1 adhesin and the Hag hemagglutinin
Evading the complement system, one of the body’s first-line defenses against bacteria, is another area where M. catarrhalis excels. The bacterium hijacks host regulatory proteins that normally protect the body’s own cells from complement attack, repurposing them as a shield. It recruits C4b-binding protein and factor H to block complement pathways, and it grabs vitronectin to interfere with the final stage of complement attack where pores are punched in the bacterial membrane.19PubMed. Complement evasion by the human respiratory tract pathogens Haemophilus influenzae and Moraxella catarrhalis The bacterium’s lipooligosaccharide, a component of its outer membrane, also contributes to complement resistance, and this structural protection depends on an internal cellular system called the disulphide bond formation pathway.20PubMed. Deciphering the genetic basis of Moraxella catarrhalis complement resistance: a critical role for the disulphide bond formation system
The Beta-Lactamase Problem
Perhaps the most clinically relevant feature of M. catarrhalis is that the overwhelming majority of strains now produce beta-lactamase enzymes, which break down penicillin-type antibiotics. This was not always the case; as recently as the 1970s, most isolates were susceptible to penicillin. Today the picture is starkly different. In a European surveillance study, ninety-two percent of isolates were beta-lactamase positive.21PubMed Central. Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates In North America, surveillance data from nearly 8,000 isolates found BRO-1 accounted for the vast majority of beta-lactamase production, with BRO-2 present in only a small fraction of strains.22PubMed Central. Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004) Studies from India have confirmed similarly high rates, with all tested isolates in one hospital report carrying the BRO-1 gene.23PubMed Central. Moraxella catarrhalis: A Cause of Concern with Emerging Resistance and Presence of BRO Beta-Lactamase Gene—Report from a Tertiary Care Hospital in South India
In practical terms, this means plain amoxicillin or penicillin should not be relied on to treat a confirmed M. catarrhalis infection. Adding a beta-lactamase inhibitor like clavulanic acid restores effectiveness; the amoxicillin-clavulanate combination consistently works against these strains.24PubMed Central. Moraxella catarrhalis: A Cause of Concern with Emerging Resistance and Presence of BRO Beta-Lactamase Gene—Report from a Tertiary Care Hospital in South India Second- and third-generation cephalosporins also retain activity. Macrolides and fluoroquinolones are sometimes used, though at least one study has flagged emerging resistance to both classes, suggesting they should not be automatically assumed to work.25PubMed Central. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections
Shielding Neighbors From Antibiotics
The beta-lactamase production by M. catarrhalis has consequences that go beyond its own survival. In mixed infections, the enzyme it secretes can protect nearby bacteria that would otherwise be killed by penicillin-type drugs. This has been demonstrated in biofilm experiments where M. catarrhalis grown alongside Streptococcus pneumoniae effectively shielded the pneumococcus from amoxicillin and penicillin, allowing the pneumococcus to survive at antibiotic concentrations that should have killed it.26PubMed Central. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system This indirect pathogenic role matters because ear infections and respiratory infections are frequently polymicrobial, and treating one bacterium may fail if a co-infecting M. catarrhalis is neutralizing the antibiotic. It is one more reason clinicians may choose amoxicillin-clavulanate over plain amoxicillin for ear infections in young children, especially when recurrence is a concern.
How It Gets Identified in the Lab
Recognizing M. catarrhalis in clinical samples is not especially difficult, but it does require distinguishing it from Neisseria species, which look similar under the microscope. The butyrate esterase spot test is one of the quickest ways to make that distinction: M. catarrhalis produces butyrate esterase, while Neisseria species do not.27PubMed Central. Butyrate esterase (4-methylumbelliferyl butyrate) spot test, a simple method for immediate identification of Moraxella (Branhamella) catarrhalis Several rapid tests exploiting this difference can provide same-day identification.28PubMed Central. Comparison of three rapid methods, tributyrine, 4-methylumbelliferyl butyrate, and indoxyl acetate, for rapid identification of Moraxella catarrhalis Commercial card systems that combine several enzyme tests on a single card can simultaneously identify M. catarrhalis, N. gonorrhoeae, and N. meningitidis with accuracy above ninety-eight percent.29PubMed. Evaluation of the BactiCard Neisseria for identification of pathogenic Neisseria species and Moraxella catarrhalis
Colony morphology also offers a clue: M. catarrhalis colonies on agar can be pushed across the plate surface intact, sometimes described as having a “hockey puck” quality. This is a simple, low-tech observation that experienced microbiologists use alongside the enzyme tests.
Iron Acquisition and Survival on Mucosal Surfaces
Bacteria need iron to grow, and the human body goes to considerable lengths to keep iron locked away from invaders, bound to carrier proteins like transferrin in the blood and lactoferrin on mucosal surfaces. M. catarrhalis has evolved ways to steal iron directly from both of these host proteins without producing siderophores, the iron-scavenging molecules many other bacteria rely on.30PubMed Central. Growth of Moraxella catarrhalis with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production When iron is scarce, the bacterium produces specialized outer membrane proteins designed to grab it from host carriers. These iron-acquisition receptors include a protein called TbpA, which is essential for stripping iron from transferrin.31PubMed. Construction and characterization of Moraxella catarrhalis mutants defective in expression of transferrin receptors This iron-pirating system likely helps the bacterium establish and maintain colonization on the oxygen-rich but iron-poor mucosal surfaces of the nose and throat.
How the Immune System Responds
Healthy adults generally keep M. catarrhalis in check, and part of the reason appears to be antibody responses targeting its surface proteins. Serological studies have shown that healthy adults typically have high levels of antibodies against the adhesive and functional regions of UspA1, UspA2, and another outer membrane protein called MID, whereas young children have low levels of these antibodies.32American Society for Microbiology / Infection and Immunity. Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2 This pattern neatly mirrors the clinical picture: children get sick from M. catarrhalis far more often than adults do. The antibodies adults develop against MID are bactericidal, meaning they help kill the bacteria directly, and they work additively with antibodies targeting UspA1 and UspA2.33American Society for Microbiology / Infection and Immunity. Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2 COPD patients are an interesting middle case: most have robust antibody levels, but some do not, and those patients tend to mount a detectable antibody rise after acquiring a new strain, suggesting their immune system is playing catch-up.
Vaccine Development
No licensed vaccine against M. catarrhalis exists, but there has been sustained research interest in developing one, driven by the burden of childhood ear infections and COPD exacerbations. The surface proteins that the bacterium uses for adhesion and immune evasion are natural vaccine candidates because they are exposed on the cell surface and provoke immune responses.34PubMed Central. Vaccine targets against Moraxella catarrhalis
Several protein antigens have shown promise in animal models. A comprehensive screen tested 23 candidates and found that multiple proteins helped mice clear the bacteria from their lungs faster than controls, with a few achieving statistically significant reductions in bacterial load.35PLoS ONE. Comprehensive Antigen Screening Identifies Moraxella catarrhalis Proteins That Induce Protection in a Mouse Pulmonary Clearance Model Two other proteins, Msp22 and Msp75, have been characterized as antigenically conserved across strains and capable of boosting pulmonary clearance in mice when delivered either by injection or through a nasal route.36PubMed Central. Characterization of Proteins Msp22 and Msp75 as Vaccine Antigens of Moraxella catarrhalis The challenge, as with many mucosal pathogens, is translating promising mouse data into a vaccine that works reliably in humans. The high antigenic diversity of M. catarrhalis and the fact that natural infection does not produce long-lasting immunity in children both complicate the path forward.
Genomic Diversity and Two Major Lineages
Genomic studies have revealed that M. catarrhalis is not a single uniform population. Comparative analysis of dozens of strains identified at least two major lineages, sometimes called seroresistant and serosensitive, plus a smaller divergent group. These lineages have evolved independently, with the serosensitive lineage accumulating more genetic differences between strains, suggesting it has either been around longer or evolves faster.37PubMed Central. Comparative Genomic Analyses of the Moraxella catarrhalis Serosensitive and Seroresistant Lineages Demonstrate Their Independent Evolution There is extensive horizontal gene transfer within each lineage, and notably, beta-lactamase genes have been shared at very high rates between the two lineages, which helps explain how resistance spread so quickly through the species.38PubMed Central. Comparative Genomic Analyses of the Moraxella catarrhalis Serosensitive and Seroresistant Lineages Demonstrate Their Independent Evolution
Further genomic work has found that the lineages also differ in their restriction-modification systems, the molecular machinery bacteria use to distinguish their own DNA from foreign DNA. Certain types of these systems correlate with one lineage over the other, which may influence how readily the lineages pick up new genes from their environment or from each other.39Genome Biology and Evolution. Moraxella catarrhalis Restriction–Modification Systems Are Associated with Phylogenetic Lineage and Disease Understanding this diversity matters for vaccine design, since a vaccine that targets proteins from one lineage may not protect equally against strains from another.